A side-by-side comparison of two Healthcare investors: Catalio Capital Management (Power Score 82/100) and Shenzhen Capital Group (Power Score 80/100), both ranked among the most active firms tracked in this category.
| Catalio Capital Management | Shenzhen Capital Group | |
|---|---|---|
| Power Score™ | 82/100 | 80/100 |
| Assets Managed | $2B (the homepage prints "$2B In assets under management *as of 10/01/2025"; the raw date form is carried here because for a US filer 10/01/2025 reads as 1 October 2025) | US$50B+ (approx.; the firm's figure is RMB 360.273bn of paid-in capital across all funds it and its subsidiaries manage at 31 December 2024, per its 2025 bond credit rating report - paid-in fund scale, not net asset value) |
| Founded | 2020 | 1999 |
| Headquarters | New York, NY | Shenzhen, China |
| Sectors | Healthcare, Biotech, Medical Devices, Diagnostics, Life Sciences, Data | Semiconductors, Technology, Robotics, Industrial Manufacturing, Advanced Manufacturing, Clean Energy, Biotech, Pharmaceuticals, Infrastructure Software |
Catalio Capital Management is an SEC-registered investment adviser (CRD 310374, SEC file 801-121976) that describes itself as focused on the full lifecycle of innovative healthcare investing, across private, public and credit markets. It runs four stated strategies: Private Equity and Venture Capital, investing in privately held innovative healthcare companies at all stages from inception to IPO; Structured Opportunities, providing senior-secured financing to healthcare innovators; Public Equities, a fundamental equity long/short strategy investing in global healthcare equities across innovative drugs, devices, diagnostics and data; and Co-Investments offering limited partners direct access to selected deals. The firm operates from New York, Washington DC and London, and states that it works with a network of more than 45 Venture Partners who hold equity interests across all Catalio strategies. It is a multi-strategy healthcare investment manager rather than a pure venture partnership.
View full Catalio Capital Management profile →Shenzhen Capital Group describes itself on its own site as a state-owned comprehensive investment group whose core business is venture capital, and says its business spans venture capital, real estate investment, public mutual funds and asset securitisation. Within venture capital it says it manages venture funds, funds of funds, S funds and buyout funds, and it has managed government guidance funds since setting up China's first government guidance sub-fund with the Suzhou municipal government in 2007 and taking on entrusted management of the Shenzhen municipal guidance fund from 2016. Chairman Zuo Ding stated in a 25 February 2026 article on the group's site that more than 85 per cent of the 1,800 plus companies the group has directly invested in are start-up stage or growth stage, that more than 90 per cent are hard technology companies, and that the focus areas cover semiconductors, robotics, new materials, biopharmaceuticals and industrial software. The group's investment departments are organised by both sector (information technology, high-end equipment, general equipment, new materials, new energy, biopharmaceuticals) and region (Greater Bay Area, North China, Northeast, Central China, Southeast, Jiangsu, Shanghai, West China). Its wholly owned subsidiary Red Soil Innovation Fund Management, set up in June 2014, was the first public mutual fund management company in China established by a private equity institution.
View full Shenzhen Capital Group profile →